Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunoth
Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste
Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.
A study has shown that a mobile game can be used to gather symptom data from children undergoing treatment for cancer, and potentially might also be used to provide personalised management
The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o